BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Bone cancer AND DDX5, HLR1, 1655, ENSG00000108654, P17844, DKFZp686J01190, p68, G17P1, HUMP68 AND Treatment
6 results:

  • 1. Programmable DNA hydrogel provides suitable microenvironment for enhancing autophagy-based therapies in intervertebral disc degeneration treatment.
    Qingxin S; Kai J; Dandan Z; Linyu J; Xiuyuan C; Yubo F; Kun W; Yingchao H; Hao C; Jie S; Zhi C; Hongxing S
    J Nanobiotechnology; 2023 Sep; 21(1):350. PubMed ID: 37759249
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast cancer.
    Tentler JJ; Lang J; Capasso A; Kim DJ; Benaim E; Lee YB; Eisen A; Bagby SM; Hartman SJ; Yacob BW; Gittleman B; Pitts TM; Pelanda R; Eckhardt SG; Diamond JR
    BMC Cancer; 2020 Nov; 20(1):1063. PubMed ID: 33148223
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
    Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
    Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Acquired dependence of acute myeloid leukemia on the DEAD-box RNA helicase ddx5.
    Mazurek A; Park Y; Miething C; Wilkinson JE; Gillis J; Lowe SW; Vakoc CR; Stillman B
    Cell Rep; 2014 Jun; 7(6):1887-99. PubMed ID: 24910429
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Lung transplantation for bronchiolitis obliterans syndrome after allo-SCT.
    Holm AM; Riise GC; Hansson L; Brinch L; Bjørtuft O; Iversen M; Simonsen S; Fløisand Y
    Bone Marrow Transplant; 2013 May; 48(5):703-7. PubMed ID: 23064037
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.
    De Clercq E
    Pharmacol Ther; 2010 Dec; 128(3):509-18. PubMed ID: 20826182
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.